Moderna Awarded $590 Million for Bird Flu Vaccine Development
The Department of Health and Human Services (HHS) will award roughly $590 million to Moderna to accelerate the development of mRNA-based pandemic influenza vaccines, including vaccines for avian flu strains, to ensure the United States is better prepared for future potential pandemics, according to a recent HHS news release.
Moderna is down 80% from its 52-week high as revenues continue to fall and the new RSV vaccine has performed poorly. Read my ...
Moderna cut its 2025 sales forecast by $1 billion on Monday, hurt by a slow adoption of its respiratory syncytial virus (RSV) ...
In addition to reporting 2024 revenue at the lower end of its previous guided range, Moderna issued a disappointing forward ...
The company's newer product, an RSV ( respiratory syncytial virus) vaccine, has also underperformed, contributing "minimal ...
Merck shares trade at a significant discount to peers. The company faces challenges, but there are reasons to be bullish.
Moderna’s mRNA-1403 is a messenger RNA-based trivalent vaccine candidate designed to protect against multiple norovirus genotypes. Moderna provided an update on the status of its trial investigating a ...
The Cambridge-based company said it expects 2025 revenue of between $1.5 billion to $2.5 billion, down from its previous projection of between $2.5 billion and $3.5 billion.
The stellar efficacy and safety profile of Moderna's covid vaccine offered rapid validation of the firm's mRNA technology. Its mRNA technology could allow the firm to compete in a wide range of ...
Otherwise, the study will continue to a second season, Moderna said. An independent group has informed the company that a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback